Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryJapanJapan
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty


Contact us for more batch information
Select Batch
Resource Download


Catalog No. T40795Cas No. 685119-25-9
BNTA is a potent extracellular matrix (ECM) modulator. In a rat model of arthritis, BNTA modulates arthritis by promoting the synthesis of cartilage structural molecules on chondrocytes through the induction of superoxide dismutase 3 (SOD3) and regulating chondrogenesis through superoxide anion elimination.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Pack SizePriceAvailabilityQuantity
1 mg$84In Stock
5 mg$198In Stock
10 mg$328In Stock
25 mg$637In Stock
50 mg$892In Stock
100 mg$1,220In Stock
500 mg$2,450In Stock
1 mL x 10 mM (in DMSO)$198In Stock
Bulk & Custom
Add to Cart
View More

Related Compound Libraries of "BNTA"

Product Introduction

BNTA is a potent extracellular matrix (ECM) modulator. In a rat model of arthritis, BNTA modulates arthritis by promoting the synthesis of cartilage structural molecules on chondrocytes through the induction of superoxide dismutase 3 (SOD3) and regulating chondrogenesis through superoxide anion elimination.
In vitro
BNTA (0.01-10 μM; 1-7 days) exhibits no reduction in cell viability for human osteoarthritis chondrocytes and primary chondrocytes isolated from rats.[1]
BNTA (0.1 μM; 2 days) induces a significant elevation in SOX9 protein expression. Notably, BNTA markedly enhances the protein levels of COL2A1 and SOX9 in rat osteoarthritis (OA) chondrocytes induced by IL1β.[1]
BNTA (0.01-10 μM; 6 hours) enhances the expression levels of extracellular matrix (ECM)-related genes, including COL2A1, ACAN, proteoglycan 4 (PRG4), and SRY-box 9 (SOX9) in human osteoarthritis (OA) chondrocytes. In IL1β-induced rat OA chondrocytes, BNTA elevates Col2a1, Acan, Prg4, and Sox9 mRNA levels, with the most significant effects observed around 0.1 μM.[1]
BNTA (10 μM; 5 days) increases proteoglycan staining in ATDC5 cells.[1]
BNTA (0.01-1 μM; 2 or 3 weeks) enhances anabolism and inhibits inflammatory response in osteoarthritis cartilage explants.[1]
In vivo
BNTA (0.015-1.5 mg/kg; intra-articular injection; twice a week for 4 and 8 weeks; Male SD rats ) attenuated post-traumatic osteoarthritis development after intra-articular injection well tolerated and could attenuate OA progression developed after anterior cruciate ligament transection (ACLT) in rats.[1]
Chemical Properties
Molecular Weight456.76
Cas No.685119-25-9
Storage & Solubility Information
Storage Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Solubility Information
DMSO: 60 mg/mL (131.36 mM)
Solution Preparation Table
1 mM2.1893 mL10.9467 mL21.8933 mL109.4667 mL
5 mM0.4379 mL2.1893 mL4.3787 mL21.8933 mL
10 mM0.2189 mL1.0947 mL2.1893 mL10.9467 mL
20 mM0.1095 mL0.5473 mL1.0947 mL5.4733 mL
50 mM0.0438 mL0.2189 mL0.4379 mL2.1893 mL
100 mM0.0219 mL0.1095 mL0.2189 mL1.0947 mL


  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
1 Enter information below:
2 Enter the in vivo formulation:
%Tween 80

Dose Conversion

You can also refer to dose conversion for different animals. More

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc